AnaptysBio, Inc. AN6.F Stock
AnaptysBio, Inc. Price Chart
AnaptysBio, Inc. AN6.F Financial and Trading Overview
| AnaptysBio, Inc. stock price | 21.2 EUR |
| Previous Close | 17 EUR |
| Open | 17 EUR |
| Bid | 17 EUR x 0 |
| Ask | 17.2 EUR x 0 |
| Day's Range | 17 - 17 EUR |
| 52 Week Range | 16.7 - 30.6 EUR |
| Volume | 50 EUR |
| Avg. Volume | 8 EUR |
| Market Cap | 458.36M EUR |
| Beta (5Y Monthly) | -0.14014 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.67 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 35.33 EUR |
AN6.F Valuation Measures
| Enterprise Value | 35.54M EUR |
| Trailing P/E | N/A |
| Forward P/E | -5.1051054 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 42.87336 |
| Price/Book (mrq) | 2.4035063 |
| Enterprise Value/Revenue | 3.325 |
| Enterprise Value/EBITDA | -0.273 |
Trading Information
AnaptysBio, Inc. Stock Price History
| Beta (5Y Monthly) | -0.14014 |
| 52-Week Change | -17.15% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 30.6 EUR |
| 52 Week Low | 16.7 EUR |
| 50-Day Moving Average | 18.73 EUR |
| 200-Day Moving Average | 23.63 EUR |
AN6.F Share Statistics
| Avg. Volume (3 month) | 8 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 26.49M |
| Float | 15.17M |
| Short Ratio | N/A |
| % Held by Insiders | 0.31% |
| % Held by Institutions | 120.22% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -1225.38% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -13.91% |
| Return on Equity (ttm) | -52.40% |
Income Statement
| Revenue (ttm) | 10.69M EUR |
| Revenue Per Share (ttm) | 0.38 EUR |
| Quarterly Revenue Growth (yoy) | 41.60% |
| Gross Profit (ttm) | -78511000 EUR |
| EBITDA | -130327000 EUR |
| Net Income Avi to Common (ttm) | -136724000 EUR |
| Diluted EPS (ttm) | -4.39 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 431.15M EUR |
| Total Cash Per Share (mrq) | 16.28 EUR |
| Total Debt (mrq) | 19.06M EUR |
| Total Debt/Equity (mrq) | 9.97 EUR |
| Current Ratio (mrq) | 12.213 |
| Book Value Per Share (mrq) | 7.073 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -77147000 EUR |
| Levered Free Cash Flow (ttm) | -47729500 EUR |
Profile of AnaptysBio, Inc.
| Country | Germany |
| State | CA |
| City | San Diego |
| Address | 10770 Wateridge Circle |
| ZIP | 92121-5801 |
| Phone | 858 362 6295 |
| Website | https://www.anaptysbio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 96 |
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 trial for the treatment of generalized pustular psoriasis; Rosnilimab, an anti-PD-1 agonist antibody program designed to suppress T-cell driven inflammatory diseases by augmenting signaling through PD-1 or targeted depletion of PD-1+ T cells; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Q&A For AnaptysBio, Inc. Stock
What is a current AN6.F stock price?
AnaptysBio, Inc. AN6.F stock price today per share is 21.2 EUR.
How to purchase AnaptysBio, Inc. stock?
You can buy AN6.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for AnaptysBio, Inc.?
The stock symbol or ticker of AnaptysBio, Inc. is AN6.F.
Which industry does the AnaptysBio, Inc. company belong to?
The AnaptysBio, Inc. industry is Biotechnology.
How many shares does AnaptysBio, Inc. have in circulation?
The max supply of AnaptysBio, Inc. shares is 26.76M.
What is AnaptysBio, Inc. Price to Earnings Ratio (PE Ratio)?
AnaptysBio, Inc. PE Ratio is now.
What was AnaptysBio, Inc. earnings per share over the trailing 12 months (TTM)?
AnaptysBio, Inc. EPS is -5.67 EUR over the trailing 12 months.
Which sector does the AnaptysBio, Inc. company belong to?
The AnaptysBio, Inc. sector is Healthcare.